QuarterWatch™ Reports

An independent perspective on emerging drug risks

QuarterWatch™ is published four times a year as a public service to provide an independent perspective on emerging drug risks. This scientific publication uses as its primary source recently released reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

Browse Issues

A surge in reports for montelukast (SINGULAR) is linked to FDA Early Communication that it is studying an association with psychiatric side effects • A massive recall of the heart drug digoxin (DIGITEK brand) led to reports of more than 600 patient deaths, but a direct link to defective tablets was hard to assess.